Value
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.1 |
| P/S | 9.7 |
| EV/EBITDA | 6.6 |
| Fwd P/E | 9.3 |
| PEG | 9.2 |
| Analyst target | 7.5 |
- ▸Forward P/E: 9.9x
- ▸PEG: 0.63
- ▸Attractively valued
PAHC · Why this verdict
Why Phibro Animal Health Corporatio (PAHC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Phibro Animal Health beat consensus estimates in 4 consecutive quarters with average positive surprise of 16.7%, including a 29.9% beat in February 2026 and a 21.1% beat in November 2025, demonstrating consistent above-expectations delivery. Earnings | The company beats consensus estimates in at least 3 of the next 4 quarters with average surprise remaining above 8%. | →Stable |
| CounterAnimal health product companies are subject to livestock cycle volatility; any downturn in hog or cattle cycles could rapidly reverse the beat streak as end-market demand contracts. | ||
Return on equity of 30% places Phibro Animal Health in a superior tier relative to pharmaceutical sector peers, with the peer-rank comparison also showing superior ROE versus competitors. Quality breakdown | Return on equity remains above 22% for at least 3 of the next 4 reporting periods. | →Stable |
| CounterHigh ROE in a company with debt-to-equity of 2.2 is partly driven by leverage amplification rather than genuine operational superiority; normalizing for the leverage level would reduce the effective return to more moderate levels. | ||
Free cash flow is negative 19% of net income, flagged as a red flag in the quality assessment, indicating the business is consuming cash despite strong reported earnings, which is a value-trap signal when combined with the high leverage. Quality breakdown | Free cash flow turns positive as a percentage of net income within 4 reporting periods as capital expenditure normalizes. | →Stable |
| CounterSpecialty animal health companies regularly invest heavily in product development and manufacturing capacity; negative free cash flow during an investment cycle may represent growth spending rather than earnings quality deterioration. | ||
Debt-to-equity of 2.2 combined with negative free cash flow triggers 2 of 5 value-trap warning flags in the data, suggesting the attractive forward price-to-earnings of 9.7x may not be accessible to equity holders if debt service consumes the available cash. Bear case | Debt-to-equity declines below 1.8 within 12 months and value-trap flag count falls to 1 or fewer. | →Stable |
| CounterThe forward price-to-earnings of 9.7x at a PEG of 0.61 still represents attractive valuation relative to growth; if earnings continue to grow at the current pace, the leverage will naturally delever over time. | ||
Phibro Animal Health beat consensus estimates in 4 consecutive quarters with average positive surprise of 16.7%, including a 29.9% beat in February 2026 and a 21.1% beat in November 2025, demonstrating consistent above-expectations delivery.
→StableEarnings
- Expectation
- The company beats consensus estimates in at least 3 of the next 4 quarters with average surprise remaining above 8%.
CounterAnimal health product companies are subject to livestock cycle volatility; any downturn in hog or cattle cycles could rapidly reverse the beat streak as end-market demand contracts.
Return on equity of 30% places Phibro Animal Health in a superior tier relative to pharmaceutical sector peers, with the peer-rank comparison also showing superior ROE versus competitors.
→StableQuality breakdown
- Expectation
- Return on equity remains above 22% for at least 3 of the next 4 reporting periods.
CounterHigh ROE in a company with debt-to-equity of 2.2 is partly driven by leverage amplification rather than genuine operational superiority; normalizing for the leverage level would reduce the effective return to more moderate levels.
Free cash flow is negative 19% of net income, flagged as a red flag in the quality assessment, indicating the business is consuming cash despite strong reported earnings, which is a value-trap signal when combined with the high leverage.
→StableQuality breakdown
- Expectation
- Free cash flow turns positive as a percentage of net income within 4 reporting periods as capital expenditure normalizes.
CounterSpecialty animal health companies regularly invest heavily in product development and manufacturing capacity; negative free cash flow during an investment cycle may represent growth spending rather than earnings quality deterioration.
Debt-to-equity of 2.2 combined with negative free cash flow triggers 2 of 5 value-trap warning flags in the data, suggesting the attractive forward price-to-earnings of 9.7x may not be accessible to equity holders if debt service consumes the available cash.
→StableBear case
- Expectation
- Debt-to-equity declines below 1.8 within 12 months and value-trap flag count falls to 1 or fewer.
CounterThe forward price-to-earnings of 9.7x at a PEG of 0.61 still represents attractive valuation relative to growth; if earnings continue to grow at the current pace, the leverage will naturally delever over time.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Phibro Animal Health beat earnings estimates in all 4 of the last 4 quarters with average surprise of 16.7% and a return on equity of 30%, but carries negative free cash flow at 19% of net income and a debt-to-equity ratio of 2.2 that raises value-trap warning flags alongside the attractive forward price-to-earnings of 9.7x.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 5.6 |
| Gross margin | 2.5 |
| Op margin | 5.0 |
| Net margin | 3.2 |
| Current ratio | 9.8 |
| FCF quality | 0.0 |
| Moat | 6.0 |
| Piotroski F | 7.8 |
- ▸Excellent ROE: 30%
- ▸Earnings quality RED FLAG: -19% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
5.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.1 |
| EPS growth | 5.1 |
Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.8 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 4.5 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 8.9 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 36%
Insider
3.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.2 |
| holder change | 5.2 |
- ▸Notable insider selling — $4,194,807 (0.311% of mkt cap)
Peer rank
5.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.8 |
| quality rank | 7.3 |
| growth rank | 6.3 |
- ▸Superior ROE vs peers
Technical
0.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.0 |
| 52w position | 1.2 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.5 |
| days to cover | 7.4 |
| volatility | 3.1 |
| put call | 8.3 |
| implied vol | 0.1 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 2.8 |
- ▸High IV: 80%
- ▸Above max pain $30
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 5.2 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 144.0%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:5.7>=5.5
- ASYMMETRY:1.9>=1.5
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:52d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- INSIDER:0.31%=HEAVY
Warning (2)
- DEATH_CROSS:momentum=5.7>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.91
Upside
+18.0%
Downside
9.4%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 62
EdgeInst Constrain — Small cap ($1.3B) below institutional reach
SuitabilitySpeculative — Drawdown -44% (>40% off 52w high)
Investment implication
The F-path SELL output reflects an overall score of 4.1 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 8.5) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( INSIDER:0.31%=HEAVY) reinforce the read. Current asymmetry R:R is 1.91 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 8.5, Catalyst at 7.0, and Sentiment at 6.3; the weakest are Technical at 0.7, Insider at 3.5, and Growth at 5.1. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 1.91 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters.
- P2Strong Return On Equity
Trip ifReturn on equity falls below 18% for 2 consecutive reporting periods.
- P3Negative Free Cash Flow Red Flag
Trip ifFree cash flow remains below negative 30% of net income for 2 consecutive quarters.
- P4High Leverage Value Trap Signals
Trip ifDebt-to-equity ratio rises above 3.0 in any single reporting period.